Importance: The US veteran population represents a unique cohort of @entity1 in whom @entity1082 )-related @entity213 ( @entity213 ) has yet to be investigated. Objective: To investigate the incidence and characteristics of @entity213 . Design, Setting, and @entity1 : Retrospective medical record review including @entity1 with @entity213 diagnosed between January 1, 2010, and November 15, 2013, from the VA Greater Los Angeles Healthcare System. Data were collected between November 16, 2013, and June 19, 2014, and analyzed between June 20, 2014, and March 26, 2015. Exposures: Chemoradiation therapy, radiation therapy, surgery, or no treatment. Main Outcomes and Measures: We determined HPV positivity by @entity986 testing. Demographic and clinicopathologic information and overall survival were extracted from medical records. Results: We identified 150 @entity1 with the diagnosis of @entity213 . Sixty-nine @entity1 had @entity5 (46%), and 65 (43%) had @entity5 (16 did not have HPV testing). Age at diagnosis ranged from 44 to 94 years (mean, 64.6   [SD, 8.0] years), and median (interquartile range) follow-up was 16.7 (8.7-27.3) years. @entity5 location differed significantly between the 2 groups, with an HPV-positive predominance in the oropharynx (43 of 57 [75%]; P   <   .001). The HPV-positive @entity1 were more likely to be treated primarily with combined chemoradiation therapy than radiation therapy or surgery (P   <   .001). T4 @entity5 had a nearly 9 times greater rate of mortality compared with T1 @entity5 (HR, 8.52 [95% CI, 2.60-18.40; P   <   .001); N3 disease was associated with 7.18 times greater mortality (HR, 7.18 [95% CI, 1.99-12.26]; P   <   .001) compared with N1 disease; and M1 disease was associated with 6.0 times greater mortality (HR, 5.99 [95% CI, 2.59-13.81]; P   <   .001). There were 42 total deaths during follow-up, 25 in the HPV-negative group and 17 in the HPV-positive group, with a nonsignificantly higher overall survival among HPV-positive @entity1 independent of @entity285 or @entity286 use history (P   =   .09). Conclusions and Relevance: Previous studies have found that the proportion of @entity213 in the general population ranges between 20% and 75%. Although the incidence of @entity213 in the Veterans Affairs population is comparable, these @entity1 have unique risk factors and demographic characteristics that may suggest different prognostic factors for @entity213 in this population. Nonetheless, @entity5 still seem to portend a better overall prognosis regardless of @entity285 or @entity286 history among the Veterans Affairs population.

Characteristics of XXXX -Associated Head and Neck Cancers in a Veteran Population.

@entity1 :: ('9606', 'Species') :: ['patients', 'Participants'] @entity286 :: ('4097', 'Species') :: ['tobacco'] @entity986 :: ('1029', 'Gene') :: ['p16'] @entity5 :: ('MESH:D009369', 'Disease') :: ['HPV-negative tumors', 'HPV-positive tumors', 'Tumor', 'tumors'] @entity1082 :: ('10566', 'Species') :: ['human papillomavirus (HPV'] @entity285 :: ('D000431', 'Chemical') :: ['alcohol'] @entity213 :: ('MESH:C535575', 'Disease') :: ['HPV-positive HNSCC', 'HPV-positive HNSCC within the veteran population', 'head and neck squamous cell carcinoma', 'HNSCC']
@entity1082 :: (10566,Species) :: ['Human Papillomavirus']
